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Abstract
Background: The role of gene-environment interactions as risk factors for coronary heart disease
(CAD) remains largely undefined. Such interactions may involve gene mutations and disease
conditions such as type 2 diabetes mellitus (DM2) predisposing individuals to acquiring the disease.
Methods: In the present study, we assessed the possible interactive effect of DM2 and E-selectin
S128R polymorphism with respect to its predisposing individuals to CAD, using as a study model
a population of 1,112 patients and 427 angiographed controls of Saudi origin. E-selectin genotyping
was accomplished by polymerase chain reaction (PCR) amplification followed by PstI restriction
enzyme digestion.
Results: The results show that DM2 is an independent risk factor for CAD. In the absence of DM2,
the presence of the R mutant allele alone is not significantly associated with CAD (p = 0.431, OR
1.28). In contrast, in the presence of DM2 and the S allele, the likelihood of an individual acquiring
CAD is significant (odds ratio = 5.44; p = < 0.001). This effect of DM2 becomes remarkably greater
in the presence of the mutant 128R allele, as can be observed from the odds ratio of their
interaction term (odds ratio = 6.11; p = < 0.001).
Conclusion: Our findings indicate therefore that the risk of acquiring CAD in patients with DM2
increases significantly in the presence of the 128R mutant allele of the E-selectin gene.
Background
Coronary artery disease (CAD) is a complex disorder
resulting partly from interactions between genetic risk fac-
tors and environmental components. Genetic risk factors
include, among others, mutations in genes that play a role
in disease manifestation, while environmental variables
may involve events leading to functional changes in vas-
cular reactivity or lipid metabolism, for example. E-selec-
tin is a cell adhesion molecule that mediates neutrophil,
monocyte and memory T-cell adhesion to cytokine-acti-
vated endothelial cells. It is expressed in endothelial cells
at inflammation sites and plays a crucial role in monocyte
trafficking [1]. Mononuclear cells isolated from insulin-
resistant subjects have been reported to bind to endothe-
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lial cells with enhanced affinity [2-4]. Although the mech-
anisms are still poorly understood, this process seems to
be modulated by various cell-adhesion molecules and
might partly explain the increased risk of CAD associated
with insulin resistance [3]. In particular, the S128R poly-
morphism (SNP rs5361) of the E-selectin gene has been
associated with CAD, premature CAD, as well as type 2
diabetes mellitus (DM2). Thus, several studies involving
various ethnic groups including Germans, Japanese,
Americans, Chinese, Africans and Arabs have implicated
the E-selectin 128R mutant allele as a risk factor for CAD
[5-12]. Others have identified this allele as a possible
marker for post-angioplasty restenosis in CAD patients
[13].
In contrast, the relevance of E-selectin S128R polymor-
phism as a risk factor for diabetes is still not fully eluci-
dated. One study involving first degree relatives has
indicated that soluble E-selectin levels are elevated in
patients with DM2 carrying the 128R allele in comparison
with their non-diabetic relatives [10]. While a number of
studies have also associated elevated soluble E-selectin
levels with this mutation and identified it as a risk factor
for DM2 in general [14-16], others seem to point to a gen-
der (female)-related association of the soluble E-selectin
levels with the disease [17-21], independent of obesity
and elevated levels of inflammatory markers or other cell-
adhesion molecules. In contrast to the above reports, a
study by Meigs and colleagues suggested that E-selectin
variants are not important genetic risk factors for DM2 in
women [14]. Put together, it appears that the role of solu-
ble E-selectin and/or its gene polymorphism in DM2 may
depend on certain yet undefined confounding factors.
Besides, it is still unclear whether the elevation in soluble
E-selectin levels in such patients is directly linked to the
S128R mutation or not.
Thus, while the role of DM2 is well-established as an inde-
pendent risk factor for CAD, the available data on the
influence of the E-selectin in CAD patients with DM2 is
still partly controversial. Currently, the literature evaluat-
ing this possibility is limited and somewhat contradictory.
For example, a study by Endler and others suggested that
the 128R allele is not associated with CAD or an increased
risk for myocardial infarction in patients with DM2 [22].
Even less is known about possible interaction between the
E-selectin polymorphism and DM2 as potential predis-
posing factor for CAD. Nonetheless, the likelihood that
both the S128R polymorphism and DM2 may individu-
ally constitute risk factors for this vascular disease implies
that these two components may exert a synergist or addi-
tive effect of predisposing individuals to acquiring the dis-
ease. The objective of this study was, therefore, to assess
the possible interactive effect of the E-selectin S128R pol-
ymorphism and DM2 as a risk for acquiring CAD in a rel-
atively large group of patients from a homogenous Saudi
population.
Methods
Study population
Two groups of Saudi individuals were recruited for the
present study. The patient group comprised 1112 candi-
dates (767 males and 345 females; mean age 54.2 ± 11.9
yr) of Saudi Arabian descent with angiographically docu-
mented CAD. The inclusion criterion for CAD was the
presence of angiographically determined narrowing of the
coronary vessels by at least 70%. Exclusion criteria for
CAD were major cardiac rhythm disturbances, incapaci-
tating or life-threatening illness, major psychiatric illness
or substance abuse, history of cerebral vascular disease,
neurological disorder, and administration of psycho-
tropic medication. A second group of 427 individuals
(238 males and 189 females, mean age 55.6 ± 11.8 yr)
undergoing surgery for heart valvular diseases and those
who reported with chest pain, but were established to
have no significant coronary stenosis by angiography,
were recruited as angiographed controls (CON). Exclu-
sion criteria for this group included among others diseases
such as cancer, autoimmune disease, or any other disor-
ders likely to interact with variables under investigation.
Diabetic patients either had a known history of type 2 dia-
betes mellitus or were diagnosed according to the Ameri-
can Diabetes Association criteria [23]. Full informed
consent was obtained from all patients or family members
before participating in the study. This study was per-
formed in accordance with the Declaration of Helsinki as
adopted and promulgamated by the US National Insti-
tutes of Health, as well as rules and regulations laid down
by the Hospital's Ethics Committee.
Detection of the E-selectin S128R polymorphism
Five ml of peripheral blood were collected in EDTA tubes
from all participating individuals. DNA was extracted
using the Puregene kit from Gentra Systems (Minneapo-
lis, MN, USA), and stored in aliquots at -20°C until
required.
The determination of E-selectin polymorphism was car-
ried out by polymerase chain reaction (PCR) amplifica-
tion followed by PstI restriction enzyme digestion, as
described previously [8,24]. The sizes of the digested
amplicons were determined using the 50-bp ladder
(Amersham Pharmacia Biotech, Piscataway, NJ, USA).
The A > C nucleotide change at position 561 of the E-
selectin gene (corresponding to S > R amino acid change
at codon 128) abolishes a recognition site for the PstI
restriction enzyme. As a result, homozygous A/A (S/S)
genotype produces two fragments of 123 and 63 bp in size
following restrictive digestion with this enzyme. Hetero-
zygous A/C (S/R) genotype results in three fragments ofBMC Medical Genetics 2007, 8:35 http://www.biomedcentral.com/1471-2350/8/35
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186, 123 and 63 bp, and homozygous C/C (R/R) geno-
type results in one fragment of 186 bp. As a quality con-
trol, we confirmed by direct sequencing the genotype
status of 384 random samples representing the three dif-
ferent genotypes.
Statistical analysis
Analysis for the prediction of CAD was performed using
logistic regression. Gene-environment interaction terms
were estimated according to Yang and Khoury (1997)
[25]. All statistical analyses were performed using the
SPSS software version 14 (SPSS Inc., Chicago, USA). A
two-tailed p value < 0.05 was considered statistically sig-
nificant.
Results
In assessing the interaction of E-selectin genotypes with
diabetes (environment), we followed the approach of
Yang and Khoury (1997). In this model the genotype is
dichotomous (carriers versus non-carriers of E-selectin)
and the environmental exposure (diabetes) is dichoto-
mous (diabetic versus non- diabetic). In the present case,
the four possible combinations of genotype and exposure
can be displayed in a 2 × 4 table, and three categories of
joint exposure can be compared with a reference category
(for which the relative risk is by definition, 1.0). The rela-
tive risk of developing CAD in individuals who are both
genetically susceptible to the condition and have been
exposed to the environmental variable compared to the
reference group will be the measure of interaction. Thus,
the variable assumes the value of 1 (reference group) in
the absence of both diabetes and the variant S allele, the
value of 2 in the presence of both diabetes and the S allele,
3 in the absence of diabetes and presence of the mutant R
allele, and 4 in the presence of both diabetes and the R
allele.
The clinical and demographic data of the patients and
control subjects are given in Table 1. As indicated in this
table, the cases and control groups are generally compara-
ble with one another. As describe above, Table 2 gives the
interaction of DM2 and E-selectin polymorphism as a
combined risk factor for CAD. The table demonstrates
that in the absence of DM2, the presence of R mutant
allele does not have a significant effect on the develop-
ment of CAD (p = 0.431, OR 1.28). In the presence of
DM2 and the S allele, the likelihood of acquiring CAD is
significant (odds ratio = 5.44; p = < 0.001). Furthermore,
in the presence of the R mutant allele and DM2, the odds
ratio increases from 5.44 (in presence of the wild type S
allele) to 6.11 (p = < 0.001). Since DM2 is an independent
risk factor for CAD (p < 0.0001, Table 1), these results
point to an augmentation of the effect of DM2 by the pres-
ence of the R allele on individual's susceptibility to CAD.
We further performed multiple logistic regression analysis
to adjust for potentially confounding variables. Thus, in
addition to the variable representing the interaction
between diabetes and E-selectin, we included cholesterol,
triglyceride, gender, age, hypertension, family history of
CAD and smoking (Table 3). The odds ratio for the inter-
action between diabetes and E-selectin polymorphism
adjusted for all these variables was 6.41 (95% CI 3.61 –
11.37), which is similar to the results of the univariate
analysis given in Table 2.
Discussion
The present study investigated possible interaction
between DM2 and the E-selectin S128R polymorphism in
predisposing individuals to acquiring CAD, using a large
homogenous Saudi population as a study model. The
Table 2: Interaction of diabetes mellitus and E-selectin polymorphism in coronary artery disease
Interaction Total Controls n = 854 CAD n = 2224 odds ratio (95% C.I) P value
No diabetes * S allele 422 256 166 Reference -
No diabetes * R allele 44 24 20 1.28 [.69–2.4] 0.431
diabetes * S allele 2458 543 1915 5.44 [4.4–6.7] < 0.001
diabetes * R allele 154 31 123 6.11 [3.9–9.5] < 0.001
The data for the interaction between the S128R mutation and type 2 diabetes mellitus with regard to susceptibility of diabetic patients to acquiring 
coronary artery disease are presented in a 2 × 4 table. The four possible combinations of genotype and exposure are given in the first column of the 
table, and three categories of joint exposure are compared with the reference category of No diabetes * S allele.
Table 1: Clinical and demographic characteristics of the control 
and CAD groups
Controls CAD
Total 854 1112
Mean age (± SD) 55.7 ± 11.8 54.2 ± 11.9
Male 238 (55.7) 767 (69.0)
Smoking 191 (44.7) 344 (30.9)
Diabetes 287 (67.2) 1019 (91.6)
Hypertension 268 (62.8) 929 (83.7)
Family history 95 (22.4) 437 (39.7)
High cholesterol 138 (32.5) 895 (80.7)
High triglycerides 67 (15.7) 780 (70.1)
The table shows the important clinical features of the studied groups. 
The numbers in brackets give the percentages of the given values. P-
value chi by square test is 0.0001 for all variables except age, which 
gave p-value of 0.032 using Student's t-test.BMC Medical Genetics 2007, 8:35 http://www.biomedcentral.com/1471-2350/8/35
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results indicate that the presence of DM2 alone constitutes
a risk for CAD, as shown by the association between the
two disorders in the presence of the wildtype S genotype.
They also demonstrate that, while the mutant 128R alone
is not associated with CAD, its presence significantly con-
tributes to the potency of DM2 as a risk factor for acquir-
ing the disease. The fact that adjustment for other risk
factors for CAD did not alter the level of significance for
the interaction observed in this study adds weight to the
notion of its predictive power as being independent of
confounding variables. Put together, therefore, it can be
inferred that the presence of the mutant R allele of the E-
selectin gene greatly increases the likelihood of patients
with DM2 acquiring CAD.
While the importance of DM2 as an independent risk fac-
tor for CAD is well-established, the role of the E-selectin
polymorphism is still somewhat controversial, despite
several studies addressing its potential relevance as a risk
factor for CAD and DM2, respectively. Thus, currently
available data on the association of the 128R genotype
with CAD is partly inconsistent, with some studies impli-
cating it in disease manifestation [8,12,26-28], possibly
on ethnic or gender basis, and others failing to establish
such a relationship [22]. Even less convincing is the data
on its role in DM2, where the general consensus appears
to be equally divided between findings purporting an
association [18] and those advocating the opposite [22].
It is noteworthy that both CAD and DM2 are independ-
ently thought to be characterized by endothelial dysfunc-
tion [19,29,30], and an elevation in soluble E-selectin
levels has been identified as a biomarker for both disor-
ders. This scenario points to a possible link between
changes in the E-selectin levels, endothelial dysfunction
and manifestation of both diseases. Furthermore, if the
mutant 128R allele is involved in both CAD and DM2, it
follows that a combined effect of this mutation and DM2
would pose at least an additive risk for acquiring CAD. To
our knowledge, there is hardly any data in the literature
pointing to an interaction of these variables in predispos-
ing individuals to CAD. If anything, some current opinion
seems to suggest that the 128R allele may not be associ-
ated with CAD or an increased risk for myocardial infarc-
tion in patients with DM2 [22]. This is somewhat at
variance with our present findings, in that we have estab-
lished an indirect association between the allele and CAD.
Thus, particularly notable is our observation that the pres-
ence of the mutant genotype alone is not associated with
CAD, entailing that its significance as a risk for CAD
becomes apparent only in the presence of DM2. This sce-
nario would have great implications for the possible
mechanism of this interaction on the manifestation of
CAD. To begin with, as mentioned above, an elevation in
E-selectin levels appears to be a feature of certain groups
of patients with CAD, restenosis as well as DM2. The ques-
tion remains whether or not this elevation is due to the
S128R mutation. While a large number of studies availa-
ble in the literature have associated changes in DM2 or
CAD primarily with either an increase in E-selectin levels
or S128R polymorphism, only a few of these investiga-
tions have addressed this issue directly. The discrepancies
in these association studies also imply that changes
trigerred by the mutation may be partly discernible from
those resulting from elevated E-selectin levels. In this case,
the influence of the mutation may underlie various mech-
anisms in different disorders. Interesting in this regard is a
recent study by Jilma and colleagues in a human model of
endotoxin-induced tissue-factor-triggered coagulation
which found that the S128R mutation has no significant
influence on the basal or inducible soluble E-selectin, but
enhances thrombin generation substantially [31]. These
authors concluded that this coagulant effect may contrib-
ute to the linkage of this polymorphism with various
thrombotic cardiovascular disorders [31,32]. A potential
scenario, therefore, is the likelihood that the function of
the mutation in the cardiovascular disorders, such as
CAD, might be related to a prothrombotic action mecha-
nism, which may become particularly prominent in the
presence of DM2. Hence, although some studies seem to
suggest an ethnic or a gender component of the role of the
S128R polymorphism on these diseases, it would appear
that the impact of this mutation is essentially linked to the
prevalence of DM2, rather than being peculiar to certain
ethnic groups.
However, it should be noted that the genetic architecture
of atherosclerosis and/or diabetic macrovascular compli-
cations is likely to result from the contribution of many
Table 3: Multiple logistic regression analysis for the interaction 
between E-selectin genotypes and other risk factors for coronary 
artery disease
Variables Odds 
Ratio
95% C.I. for 
odds ratio
p-value
Gene – Diabetes interaction
no diabetes S (reference) 1 - -
no diabetes R 1.11 0.49–2.53 0.79
Diabetes S 6.06 4.17–8.78 0.0001
Diabetes R 6.41 3.61–11.37 0.0001
Cholesterol 2.01 1.57–2.55 0.0001
Triglycerides 6.49 4.98–8.46 0.0001
Gender 1.57 1.27–1.93 0.0001
Age 0.98 0.97–0.99 0.0001
Hypertension 2.08 1.66–2.59 0.0001
Family history 2.19 1.75–2.74 0.0001
Smoking 1.12 0.85–1.49 0.41
The table shows that the results of the univariate analysis in Table 2 
are not affected by other confounding risk factors for coronary artery 
disease.BMC Medical Genetics 2007, 8:35 http://www.biomedcentral.com/1471-2350/8/35
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genes interacting with different environmental factors. An
undoubted limitation of our study is the lack of more
comprehensive genetic analysis of potential candidate
genes. The availability of recently developed assays capa-
ble of simultaneously genotyping multiple loci should
offer appropriate approaches for the screening of geno-
type combinations of candidate genes to identify diabetic
patients at a high risk of macro-complications.
Conclusion
In conclusion, the present study points to a possible inter-
action of the E-selectin S128R polymorphism and type 2
diabetes mellitus in predisposing individuals to acquiring
coronary heart disease. While further investigations are
warranted to confirm our findings, we nonetheless believe
that our findings will contribute to the understanding of
the molecular mechanism underlying the association of
this mutation with DM2 and CAD.
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